LOGIN  |  REGISTER
C4 Therapeutics
Terns Pharmaceuticals

Integer Releases Inaugural Impact Report

August 01, 2024 | Last Trade: US$138.11 2.23 1.64
  • Report Highlights Integer’s Commitment to Minimizing Environmental Footprint,
  • Maximizing Positive Global Impact and Enhancing the Lives of Patients Worldwide 

PLANO, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced the release of its first environmental, social and governance (ESG) report, “Making a Difference: Integer’s Inaugural Impact Report.”

“I am excited to introduce Integer’s first Impact Report,” said Joseph Dziedzic, Integer president and CEO. “At Integer, we are focused on strengthening our business in a way that minimizes our environmental footprint while ultimately advancing the future of medical devices and maximizing the positive impact we have on our associates, partners, patients who use our products, and the communities where we live and work around the world.”

The report highlights Integer’s efforts and progress in the areas of health and safety, diversity and inclusion, associate engagement, charitable initiatives and associate volunteerism, along with a range of other topics.

“From the life-enhancing work our more than 11,000 associates safely perform on four continents daily, to our strong partnerships with our customers and communities, we are committed to making a difference in the lives of patients worldwide,” said McAlister Marshall, Integer senior vice president and general counsel. “This inaugural Integer Impact Report seeks to further define that impact by highlighting our strategy, approach and corresponding progress in the environmental, social and governance space.”

The full Integer Impact Report can be found here.

Learn more about Integer at www.integer.net.

About Integer®

Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.

Investor Relations:Media Relations:
Andrew SennKelly Butler
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
763.951.8312469.731.6617

Chimerix

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB